文献速递眼底病与葡萄膜炎

干细胞来源生物工程视网膜色素上皮植入物治疗地图样萎缩的1/2a期临床试验长期随访

Long-term Follow-up of a Phase 1/2a Clinical Trial of a Stem Cell-Derived Bioengineered Retinal Pigment Epithelium Implant for Geographic Atrophy.
PubMed 文献 · Ophthalmology · 2023-12-30

这项单臂、开放标签1/2a期临床试验纳入16例晚期地图样萎缩伴中心凹受累患者,15例接受支架型人胚胎干细胞来源视网膜色素上皮植入物植入,对侧未植入眼为对照。中位随访3年显示植入物安全且耐受良好,未发生非预期严重植入相关不良事件,植入眼最佳矫正视力改善>5个字母的可能性高于对照眼且下降>5个字母的可能性更低。

要点

  • 中位随访3年,眼底照相未见植入物迁移,未发生非预期严重植入相关不良事件。
  • 第二队列(9例)通过改进术中止血消除了最常见的预期严重不良事件(严重视网膜出血)。
  • 植入眼较未植入眼更可能最佳矫正视力改善>5个字母、更少可能下降>5个字母。

核心结论

  • 中位随访3年显示,支架型干细胞来源生物工程视网膜色素上皮植入物在晚期干性年龄相关性黄斑变性患者中安全且耐受良好。
  • 安全性特征及早期疗效提示,这一新方法治疗地图样萎缩值得进一步临床评估。

研究设计与样本

  • 单臂、开放标签1/2a期临床试验,获美国食品药品监督管理局批准。
  • 入组16例患者,15例成功接受植入;植入于视力较差眼,对侧未植入眼为对照。
  • 患者入组时年龄69-85岁,治疗眼因中心凹受累的地图样萎缩而法定盲(最佳矫正视力≤20/200)。
  • 主要终点为1年,此后至少每年随访一次;安全性为主要终点。

主要发现

  • 中位随访3年,眼底照相显示无植入物迁移。
  • 未发生非预期严重植入相关不良事件;第二队列(9例)通过改进术中止血消除了最常见的预期严重不良事件(严重视网膜出血)。
  • 所有患者术中或术后均出现非严重、一过性视网膜出血,符合视网膜下手术的预期。
  • 中位3年随访期间,植入眼较未植入眼更可能最佳矫正视力改善>5个字母,且更少可能下降>5个字母。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文结论指出,该新方法治疗地图样萎缩需进一步临床评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To report long-term results from a phase 1/2a clinical trial assessment of a scaffold-based human embryonic stem cell-derived retinal pigmented epithelium (RPE) implant in patients with advanced geographic atrophy (GA). DESIGN: A single-arm, open-label phase 1/2a clinical trial approved by the United States Food and Drug Administration. PARTICIPANTS: Patients were 69-85 years of age at the time of enrollment and were legally blind in the treated eye (best-corrected visual acuity [BCVA], ≤ 20/200) as a result of GA involving the fovea. METHODS: The clinical trial enrolled 16 patients, 15 of whom underwent implantation successfully. The implant was administered to the worse-seeing eye with the use of a custom subretinal insertion device. The companion nonimplanted eye served as the control. The primary endpoint was at 1 year; thereafter, patients were followed up at least yearly. MAIN OUTCOME MEASURES: Safety was the primary endpoint of the study. The occurrence and frequency of adverse events (AEs) were determined by scheduled eye examinations, including measurement of BCVA and intraocular pressure and multimodal imaging. Serum antibody titers were collected to monitor systemic humoral immune responses to the implanted cells. RESULTS: At a median follow-up of 3 years, fundus photography revealed no migration of the implant. No unanticipated, severe, implant-related AEs occurred, and the most common anticipated severe AE (severe retinal hemorrhage) was eliminated in the second cohort (9 patients) through improved intraoperative hemostasis. Nonsevere, transient retinal hemorrhages were noted either during or after surgery in all patients as anticipated for a subretinal surgical procedure. Throughout the median 3-year follow-up, results show that implanted eyes were more likely to improve by > 5 letters of BCVA and were less likely to worsen by > 5 letters compared with nonimplanted eyes. CONCLUSIONS: This report details the long-term follow-up of patients with GA to receive a scaffold-based stem cell-derived bioengineered RPE implant. Results show that the implant, at a median 3-year follow-up, is safe and well tolerated in patients with advanced dry age-related macular degeneration. The safety profile, along with the early indication of efficacy, warrants further clinical evaluation of this novel approach for the treatment of GA. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.

来源:Ophthalmology,查看原文。版权归原作者所有。

引用

  1. Humayun MS, Clegg DO, Dayan MS, et al. Long-term Follow-up of a Phase 1/2a Clinical Trial of a Stem Cell-Derived Bioengineered Retinal Pigment Epithelium Implant for Geographic Atrophy. Ophthalmology. 2023. PMID: 38160882. doi:10.1016/j.ophtha.2023.12.028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。